Quest Diagnostics
631 hedge funds and large institutions have $11.8B invested in Quest Diagnostics in 2017 Q4 according to their latest regulatory filings, with 90 funds opening new positions, 193 increasing their positions, 243 reducing their positions, and 70 closing their positions.
34% more call options, than puts
Call options by funds: $44.2M | Put options by funds: $33M
29% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 70
2% more funds holding
Funds holding: 616 → 631 (+15)
3% more capital invested
Capital invested by funds: $11.5B → $11.8B (+$308M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.84% less ownership
Funds ownership: 90.12% → 88.28% (-1.8%)
21% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 243
Top Buyers
Top Sellers
DGX Hedge Fund Activity: Q4 2017 in Review
631 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q4 2017, worth a combined $11.8B — up 2.7% from $11.5B a quarter earlier.
Buyers outnumbered sellers: 90 funds opened new DGX positions and 70 closed out — a net gain of 20 holders — while 193 added to existing stakes and 243 trimmed.
The largest buyer was Fiduciary Management Inc, opening a new position worth an estimated $197M. The largest seller was AJO LP, cutting an estimated $156M.
- 631 institutional investors held Quest Diagnostics (DGX) as of Q4 2017, up from 616 in Q3 2017.
- Funds reported $11.8B of Quest Diagnostics stock for Q4 2017, up 2.7% quarter-over-quarter.
- 90 funds opened new Quest Diagnostics positions in Q4 2017 and 70 closed out, a net change of +20 holders.
- The largest Quest Diagnostics buyer in Q4 2017 was Fiduciary Management Inc, an estimated $197M added.
- The largest Quest Diagnostics seller in Q4 2017 was AJO LP, an estimated $156M sold.
Based on aggregated 13F filings for Q4 2017.